지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 486 - 492 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in naïve patients with CHB were investigated. Methods: In this retrospective study, 152 naïve Korean patients with CHB who received 30 mg of CLV once daily for at least 12 months were investigated. Results: The cumulative rates at months 12, 24, and 36, respectively, were 65.8%, 74.7%, and 74.7% for undetectable serum hepatitis B virus (HBV) DNA (<12 IU/mL); 77.6%, 86.2%, and 86.2% for normalization of serum alanine aminotransferase (<40 IU/L); 17.6%, 23.5%, and 23.5% for hepatitis B e antigen (HBeAg) loss or seroconversion; and 6.6%, 22.5%, and 30.0% for viral breakthrough. HBeAg positivity (p=0.010), baseline serum HBV DNA level ≥6 log10 IU/mL (p=0.032) and detectable serum HBV DNA (≥12 IU/mL) at week 24 (p=0.023) were independently associated with the development of viral breakthrough. During follow-up, CLV-induced myopathy developed in 5.9% of patients. Conclusions: The results of long-term CLV therapy for the treatment of naïve patients with CHB showed a high frequency of antiviral resistance and substantial associated myopathy. Therefore, we advise that CLV should not be used as a first-line treatment for naïve patients given the availability of other more potent, safer antiviral agents.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Balakrishna Pai S / 1996 / Inhibition of hepatitis B virus by a novel L-nucleoside, 2’-fluoro-5-methyl-beta-L-arabinofuranosyl uracil / Antimicrob Agents Chemother 40 : 380
Chang TT / 2006 / A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B / N Engl J Med 354 : 1001 ~ 1010
European Association for the Study of the Liver / 2009 / EASL Clinical Practice Guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
George KK Lau / 2010 / Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study / Cl
Hadziyannis SJ / 2006 / Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years / Gastroenterology 131 : 1743 ~ 1751
Chang TT / 2006 / A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B / N Engl J Med 354 : 1001 ~ 1010
European Association for the Study of the Liver / 2009 / EASL Clinical Practice Guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
George KK Lau / 2010 / Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study / Cl
Hadziyannis SJ / 2006 / Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years / Gastroenterology 131 : 1743 ~ 1751
이 논문의 저자 정보
최근 본 자료
댓글(0)
0